Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Corvus Pharmaceuticals (CRVS) Q4 2025: $189M Financing Extends Cash Runway to 2028 as Socalitinib Clinical Momentum Builds
March 13, 2026
-
Corvus Pharmaceuticals (CRVS) Q3 2025: R&D Spend Jumps 63% as Socolitinib Pipeline Momentum Builds
November 05, 2025
-
Corvus Pharmaceuticals (CRVS) Q2 2025: $35.7M Warrant Exercise Extends Cash Runway Into 2026
August 08, 2025
-
Corvus Pharmaceuticals (CRVS) Q1 2025: $31M Warrant Exercise Extends Cash Runway, Atopic Dermatitis Data Signals Pipeline Upside
July 05, 2025